News Snapshot:
A Chinese inactivated COVID-19 vaccine candidate has been proved safe and tolerable and can induce a quick immune response, according to the findings from early and mid-stage clinical trials published in the journal The Lancet Infectious Diseases. The level of antibodies induced by the vaccine was lower than those in people who had recovered from COVID-19, whereas it was capable of protecting the human body from infections caused by the virus, the findings said. The vaccine, CoronaVac, was developed by a Chinese biopharmaceutical producer Sinovac Biotech. It was tested in randomized, double-blind and placebo-controlled phase-1 and phase-2 clinical trials involving...
